Inflammation and carnitine in hemodialysis patients
- PMID: 15647999
- DOI: 10.1053/j.jrn.2004.09.031
Inflammation and carnitine in hemodialysis patients
Abstract
The bioincompatibility of dialytic systems along with the loss of antioxidant substances via the dialysis may contribute to peripheral blood mononuclear cell (PBMC) activation and the production of inflammatory mediators, such as cytokines, oxygen radicals, and complement fragments, that may sustain a state of chronic microinflammation responsible for the pathogenesis of a variety of diseases, including atherosclerosis, anemia, and malnutrition. Moreover, during hemodialysis (HD), oxidative stress may influence several intracellular signaling enzymes, including some stress-activated kinases, such as jun-N-terminal kinase (JNK), potentially leading to PBMC activation and proinflammatory cytokine production. Recent reports suggest that L-carnitine may play an important role in balancing antioxidative systems. Therefore, we sought to evaluate the effect of L-carnitine supplementation on the PBMC responses to oxidative stress induced by different HD membranes. We observed in PBMC from cellulosic (C)-treated patients an increase in the amount of intracellular tyrosine-phosphorylated proteins and a striking activation of JNK, as compared with synthetic (S)-treated patients. On the contrary, 3 months of L-carnitine supplementation significantly lowered intracellular levels of phosphorylated proteins and JNK activity in PBMC from C-treated patients. In addition, after 180 minutes of HD, a significant decrease in global plasma antioxidant capacity was found, particularly in C-treated patients, whereas L-carnitine supplementation improved plasma antioxidant capacity levels in these patients. These observations were also confirmed by in vitro experiments, showing the ability of L-carnitine to reduce the JNK activation in normal PBMC exposed to different amounts of hydrogen peroxide. In conclusion, the uremic milieu is characterized by an enhanced inflammatory response and an increased oxidant load, affecting lipids, carbohydrates, and proteins. Regular L-carnitine supplementation in HD patients can improve cellular defense against chronic inflammation and oxidative stress, most likely by modulating the specific signal transduction cascade activated by an overproduction of proinflammatory cytokines and oxidative stress.
Similar articles
-
Coagulation cascade activation causes CC chemokine receptor-2 gene expression and mononuclear cell activation in hemodialysis patients.J Am Soc Nephrol. 2005 Aug;16(8):2477-86. doi: 10.1681/ASN.2004070621. Epub 2005 Jun 23. J Am Soc Nephrol. 2005. PMID: 15976001
-
Vitamin E-modified filters modulate Jun N-terminal kinase activation in peripheral blood mononuclear cells.Kidney Int. 2002 Aug;62(2):602-10. doi: 10.1046/j.1523-1755.2002.00458.x. Kidney Int. 2002. PMID: 12110024 Clinical Trial.
-
Role of carnitine in modulating acute-phase protein synthesis in hemodialysis patients.J Ren Nutr. 2005 Jan;15(1):13-7. doi: 10.1053/j.jrn.2004.09.008. J Ren Nutr. 2005. PMID: 15648000
-
Overproduction of reactive oxygen species in end-stage renal disease patients: a potential component of hemodialysis-associated inflammation.Hemodial Int. 2005 Jan;9(1):37-46. doi: 10.1111/j.1492-7535.2005.01116.x. Hemodial Int. 2005. PMID: 16191052 Review.
-
History of L-carnitine: implications for renal disease.J Ren Nutr. 2003 Jan;13(1):2-14. doi: 10.1053/jren.2003.50010. J Ren Nutr. 2003. PMID: 12563618 Review.
Cited by
-
Association of Low Serum l-Carnitine Levels with Peripheral Arterial Stiffness in Patients Who Undergo Kidney Transplantation.Nutrients. 2019 Aug 24;11(9):2000. doi: 10.3390/nu11092000. Nutrients. 2019. PMID: 31450550 Free PMC article.
-
Investigation of inflammatory profile in MSUD patients: benefit of L-carnitine supplementation.Metab Brain Dis. 2015 Oct;30(5):1167-74. doi: 10.1007/s11011-015-9686-9. Epub 2015 May 24. Metab Brain Dis. 2015. PMID: 26002427
-
Inflammation and L-carnitine therapy in hemodialysis patients: a review.Clin Exp Nephrol. 2015 Jun;19(3):331-5. doi: 10.1007/s10157-014-1061-3. Epub 2014 Dec 2. Clin Exp Nephrol. 2015. PMID: 25446285 Review.
-
Mitochondria: a new therapeutic target in chronic kidney disease.Nutr Metab (Lond). 2015 Nov 25;12:49. doi: 10.1186/s12986-015-0044-z. eCollection 2015. Nutr Metab (Lond). 2015. PMID: 26612997 Free PMC article. Review.
-
Neuroprotective effects of L-carnitine towards oxidative stress and inflammatory processes: a review of its importance as a therapeutic drug in some disorders.Metab Brain Dis. 2025 Feb 15;40(2):127. doi: 10.1007/s11011-025-01545-6. Metab Brain Dis. 2025. PMID: 39954226 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous